Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 21Breast Neoplasms 19Prostatic Neoplasms 12Neuroblastoma 11Multiple Myeloma 11Leukemia 11Leukemia, Myeloid, Acute 10Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Breast Neoplasms, Male 8Glioblastoma 7Ovarian Neoplasms 6Myelodysplastic Syndromes 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Fallopian Tube Neoplasms 5Colorectal Neoplasms 5Neoplasms 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic-Phase 4Hodgkin Disease 4Glioma 4Carcinoma, Ovarian Epithelial 4Uveal Melanoma 3Rhabdomyosarcoma 3Pancreatic Neoplasms 3Medulloblastoma 3Lung Neoplasms 3

Interventions

pegfilgrastim 3liposomal amphotericin B 2Vancomycin 2Filgrastim 2Caspofungin 2trametinib 1ofatumumab 1dabrafenib 1Teicoplanin 1Tazobactam 1Surveys and Questionnaires 1Ritonavir 1Quality of Life 1Povidone-Iodine 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Metformin 1Meropenem 1Lenalidomide 1Itraconazole 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Doxorubicin 1Docetaxel 1Daptomycin 1Cyclophosphamide 1Cloxacillin 1Cilastatin, Imipenem Drug Combination 1Ceftazidime 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fever × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT00001338 2008-03-04

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
65 enrolled
Breast

Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia, Sepsis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡